Document is current
Any future updates will be listed below
-
Authors
Liu, Jinan https://orcid.org/0009-0002-6042-5476
Matangi, Sudheer https://orcid.org/0009-0009-2777-5459
Malempati, Yogitha https://orcid.org/0009-0009-2999-732X
Nasir, Adnan
Rosmarin, David https://orcid.org/0009-0008-8548-2198
-
Funding
Funding for this research was provided by:
Incyte Corporation
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 21 July 2025
First Online: 19 August 2025
Declarations
:
: Jinan Liu and Adnan Nasir are employees and shareholders of Incyte Corporation. Sudheer Matangi and Yogitha Malempati are employees of Market Access Solutions, which was contracted to perform the analysis on behalf of Incyte. David Rosmarin has received research support and honoraria (consultant/speaker) from AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Dualitas, EMD Serono, Galderma, Incyte, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, and Zura Bio. David Rosmarin is an Editorial Board member of Dermatology and Therapy. David Rosmarin was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
